{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T14:35:24Z","timestamp":1787668524466,"version":"build-2736575974"},"reference-count":47,"publisher":"Public Library of Science (PLoS)","issue":"12","license":[{"start":{"date-parts":[[2022,12,7]],"date-time":"2022-12-07T00:00:00Z","timestamp":1670371200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Background<\/jats:title>\n<jats:p>Venetoclax (VEN) is the first selective small molecule Bcl-2 inhibitor approved by FDA and used in adult chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL) and some acute myeloid leukemia (AML). However, the long-term safety of VEN in large sample population was unknown. This study evaluated the adverse events (AEs) of VEN from FDA Adverse Event Reporting System (FAERS) since its approval in 2016 by data mining.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Methods<\/jats:title>\n<jats:p>The disproportionality analyses, including four algorithms of reporting odd ratio (ROR), proportional reporting ratio (PRR), bayesian configuration promotion neural network (BCPNN), and multi item gamma poisson shrinker (MGPS), were employed to quantify the signals of VEN-associated AEs.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Results<\/jats:title>\n<jats:p>From the FAERS database, a total of 8,379,682 reports were collected during the study period. After removing the duplication, the number of reports with VEN as the primary suspect (PS) was 19,107. The 19,107 cases of AEs involved 27 organ systems, 256 significant PTs which conforming to the four algorithms. Unexpected serious AEs, such as pleural effusion, splenic infarction, atrial fibrillation, skin squamous cell carcinoma, etc., have signals. The median time of occurrence of AEs related to VEN was 31 days (inter quartile range [IQR] 7\u2013131 days), and half of the reported AEs occurred within 1 month after administration.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec004\">\n<jats:title>Conclusion<\/jats:title>\n<jats:p>Our research has found new significant AEs signals of VEN, which improved its safety information in real-world after marketing approval, and contributed to its risk control of use in clinic.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0278725","type":"journal-article","created":{"date-parts":[[2022,12,7]],"date-time":"2022-12-07T18:41:58Z","timestamp":1670438518000},"page":"e0278725","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":25,"title":["A real-world pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) events for venetoclax"],"prefix":"10.1371","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4571-1327","authenticated-orcid":true,"given":"Yang","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yamin","family":"Shu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guosong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanchao","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feie","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2022,12,7]]},"reference":[{"issue":"9","key":"pone.0278725.ref001","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1007\/s40265-016-0596-x","article-title":"Venetoclax: First Global Approval","volume":"76","author":"ED Deeks","year":"2016","journal-title":"Drugs"},{"issue":"1","key":"pone.0278725.ref002","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/s13045-022-01295-3","article-title":"Clinical experiences with venetoclax and other pro-apoptotic agents in lymphoid malignancies: lessons from monotherapy and chemotherapy combination","volume":"15","author":"TE Lew","year":"2022","journal-title":"J Hematol Oncol"},{"issue":"21","key":"pone.0278725.ref003","doi-asserted-by":"crossref","first-page":"3643","DOI":"10.1042\/BCJ20170080","article-title":"Therapeutics targeting Bcl-2 in hematological malignancies","volume":"474","author":"A Ruefli-Brasse","year":"2017","journal-title":"Biochem J"},{"issue":"4","key":"pone.0278725.ref004","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.ccell.2019.09.008","article-title":"Venetoclax in Lymphoid Malignancies: New Insights, More to Learn","volume":"36","author":"R Thijssen","year":"2019","journal-title":"Cancer Cell"},{"issue":"6","key":"pone.0278725.ref005","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1097\/PPO.0000000000000408","article-title":"BCL-2 Inhibitors, Present and Future","volume":"25","author":"CE Ryan","year":"2019","journal-title":"Cancer J"},{"issue":"9","key":"pone.0278725.ref006","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1080\/10428194.2017.1283032","article-title":"Pathways and mechanisms of venetoclax resistance","volume":"58","author":"P Bose","year":"2017","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"pone.0278725.ref007","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1016\/j.cell.2007.01.037","article-title":"Programmed Anuclear Cell Death Delimits Platelet Life Span","volume":"128","author":"KD Mason","year":"2007","journal-title":"Cell"},{"issue":"5","key":"pone.0278725.ref008","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1200\/JCO.2011.34.7898","article-title":"Substantial Susceptibility of Chronic Lymphocytic Leukemia to BCL2 Inhibition: Results of a Phase I Study of Navitoclax in Patients With Relapsed or Refractory Disease","volume":"30","author":"AW Roberts","year":"2012","journal-title":"J Clin Oncol"},{"issue":"11","key":"pone.0278725.ref009","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1080\/13543784.2017.1386173","article-title":"Venetoclax for the treatment of chronic lymphocytic leukemia","volume":"26","author":"M Gentile","year":"2017","journal-title":"Expert Opin Investig Drugs"},{"issue":"2","key":"pone.0278725.ref010","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/nm.3048","article-title":"ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets","volume":"19","author":"AJ Souers","year":"2013","journal-title":"Nat Med"},{"issue":"5","key":"pone.0278725.ref011","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1177\/1060028016685803","article-title":"Venetoclax: A First-in-Class Oral BCL-2 Inhibitor for the Management of Lymphoid Malignancies","volume":"51","author":"AC King","year":"2017","journal-title":"Ann Pharmacother"},{"key":"pone.0278725.ref012","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7573\/dic.212574","article-title":"Venetoclax: evidence to date and clinical potential","volume":"8","author":"LM Ju\u00e1rez-Salcedo","year":"2019","journal-title":"Drugs Context"},{"issue":"2","key":"pone.0278725.ref013","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s40290-020-00329-w","article-title":"US Food and Drug Administration Safety Advisories and Reporting to the Adverse Event Reporting System (FAERS)","volume":"34","author":"TJ Moore","year":"2020","journal-title":"Pharm Med"},{"key":"pone.0278725.ref014","doi-asserted-by":"crossref","first-page":"862508","DOI":"10.3389\/fphar.2022.862508","article-title":"Post-Marketing Safety Concerns With Secukinumab: A Disproportionality Analysis of the FDA Adverse Event Reporting System","volume":"13","author":"Y Shu","year":"2022","journal-title":"Front Pharmacol"},{"key":"pone.0278725.ref015","doi-asserted-by":"crossref","first-page":"789","DOI":"10.2147\/CLEP.S365513","article-title":"A Real-World Disproportionality Analysis of Olaparib: Data Mining of the Public Version of FDA Adverse Event Reporting System","volume":"14","author":"Y Shu","year":"2022","journal-title":"Clin Epidemiol"},{"issue":"34","key":"pone.0278725.ref016","doi-asserted-by":"crossref","first-page":"e213","DOI":"10.3346\/jkms.2018.33.e213","article-title":"Real-world Evidence versus Randomized Controlled Trial: Clinical Research Based on Electronic Medical Records","volume":"33","author":"HS Kim","year":"2018","journal-title":"J Korean Med Sci"},{"issue":"7","key":"pone.0278725.ref017","doi-asserted-by":"crossref","first-page":"796","DOI":"10.7150\/ijms.6048","article-title":"Data Mining of the Public Version of the FDA Adverse Event Reporting System","volume":"10","author":"T Sakaeda","year":"2013","journal-title":"Int J Med Sci"},{"issue":"6","key":"pone.0278725.ref018","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/S1470-2045(16)30019-5","article-title":"Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study","volume":"17","author":"S Stilgenbauer","year":"2016","journal-title":"Lancet Oncol"},{"issue":"24","key":"pone.0278725.ref019","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1182\/blood.2020004856","article-title":"Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial","volume":"135","author":"AH Wei","year":"2020","journal-title":"Blood"},{"key":"pone.0278725.ref020","doi-asserted-by":"crossref","DOI":"10.1177\/20406207221081637","article-title":"A retrospective comparison of salvage intensive chemotherapy versus venetoclax-combined regimen in patients with relapsed\/refractory acute myeloid leukemia (AML)","volume":"13","author":"S Park","year":"2022","journal-title":"Ther Adv Hematol"},{"key":"pone.0278725.ref021","doi-asserted-by":"crossref","first-page":"5613","DOI":"10.2147\/CMAR.S316561","article-title":"Efficacy of Venetoclax Combined with Decitabine-Based Treatment for Heavily Pre-Treated Relapsed or Refractory AML Patients in a Real-World Setting","volume":"13","author":"J Tong","year":"2021","journal-title":"Cancer Manag Res"},{"issue":"1","key":"pone.0278725.ref022","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1182\/blood-2005-06-2508","article-title":"Lymphoma incidence patterns by WHO subtype in the United States, 1992\u20132001","volume":"107","author":"LM Morton","year":"2006","journal-title":"Blood"},{"issue":"4","key":"pone.0278725.ref023","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1111\/j.1600-0609.2008.01114.x","article-title":"Disease burden of chronic lymphocytic leukaemia within the European Union","volume":"81","author":"L Watson","year":"2008","journal-title":"Eur J Haematol"},{"issue":"8","key":"pone.0278725.ref024","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1080\/10428190600555819","article-title":"Sex differences in incidence and outcome of chronic lymphocytic leukemia patients","volume":"47","author":"S. Molica","year":"2006","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"pone.0278725.ref025","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1159\/000486228","article-title":"Incidence, Survival, and Risk Factors for Adults with Acute Myeloid Leukemia Not Otherwise Specified and Acute Myeloid Leukemia with Recurrent Genetic Abnormalities: Analysis of the Surveillance, Epidemiology, and End Results (SEER) Database, 2001\u20132013","volume":"139","author":"X Song","year":"2018","journal-title":"Acta Haematol"},{"key":"pone.0278725.ref026","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.blre.2019.04.005","article-title":"Epidemiology of acute myeloid leukemia: Recent progress and enduring challenges","volume":"36","author":"RM Shallis","year":"2019","journal-title":"Blood Rev"},{"issue":"5","key":"pone.0278725.ref027","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1038\/s41375-022-01556-7","article-title":"Infectious complications of targeted drugs and biotherapies in acute leukemia. Clinical practice guidelines by the European Conference on Infections in Leukemia (ECIL), a joint venture of the European Group for Blood and Marrow Transplantation (EBMT), the European Organization for Research and Treatment of Cancer (EORTC), the International Immunocompromised Host Society (ICHS) and the European Leukemia Net (ELN)","volume":"36","author":"G Maschmeyer","year":"2022","journal-title":"Leukemia"},{"issue":"10","key":"pone.0278725.ref028","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1158\/2159-8290.CD-16-0313","article-title":"Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia","volume":"6","author":"M Konopleva","year":"2016","journal-title":"Cancer Discov"},{"issue":"7","key":"pone.0278725.ref029","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia","volume":"383","author":"CD DiNardo","year":"2020","journal-title":"N Engl J Med"},{"key":"pone.0278725.ref030","article-title":"Risk of infection associated with targeted therapies for solid organ and hematological malignancies","volume":"8","author":"I Ruiz-Camps","year":"2021","journal-title":"Ther Adv Infect Dis"},{"key":"pone.0278725.ref031","doi-asserted-by":"crossref","first-page":"738915","DOI":"10.3389\/fimmu.2021.738915","article-title":"Secondary Immunodeficiency in Hematological Malignancies: Focus on Multiple Myeloma and Chronic Lymphocytic Leukemia","volume":"12","author":"A Allegra","year":"2021","journal-title":"Front Immunol"},{"issue":"1","key":"pone.0278725.ref032","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1093\/bmb\/ldn034","article-title":"The immunodeficiency of chronic lymphocytic leukaemia","volume":"87","author":"AD Hamblin","year":"2008","journal-title":"Br Med Bull"},{"issue":"3","key":"pone.0278725.ref033","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s10875-014-9995-5","article-title":"Antibody Deficiency Secondary to Chronic Lymphocytic Leukemia: Should Patients be Treated with Prophylactic Replacement Immunoglobulin?","volume":"34","author":"F Dhalla","year":"2014","journal-title":"J Clin Immunol"},{"issue":"1","key":"pone.0278725.ref034","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.beha.2009.12.004","article-title":"Infectious complications of chronic lymphocytic leukaemia: pathogenesis, spectrum of infection, preventive approaches","volume":"23","author":"VA Morrison","year":"2010","journal-title":"Best Pract Res Clin Haematol"},{"issue":"3","key":"pone.0278725.ref035","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.jhin.2019.09.020","article-title":"Invasive pulmonary aspergillosis: comparative analysis in cancer patients with underlying haematologic malignancies versus solid tumours","volume":"104","author":"RW Dib","year":"2020","journal-title":"J Hosp Infect"},{"issue":"18","key":"pone.0278725.ref036","doi-asserted-by":"crossref","first-page":"4371","DOI":"10.1158\/1078-0432.CCR-17-3761","article-title":"Comprehensive Safety Analysis of Venetoclax Monotherapy for Patients with Relapsed\/Refractory Chronic Lymphocytic Leukemia","volume":"24","author":"MS Davids","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"2","key":"pone.0278725.ref037","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/S1470-2045(18)30010-X","article-title":"Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study","volume":"19","author":"CD DiNardo","year":"2018","journal-title":"Lancet Oncol"},{"issue":"12","key":"pone.0278725.ref038","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.3390\/jof7121058","article-title":"Invasive Fungal Infections and Targeted Therapies in Hematological Malignancies","volume":"7","author":"JS Little","year":"2021","journal-title":"J Fungi"},{"issue":"2","key":"pone.0278725.ref039","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.clinthera.2017.01.003","article-title":"Management of Venetoclax-Posaconazole Interaction in Acute Myeloid Leukemia Patients: Evaluation of Dose Adjustments","volume":"39","author":"SK Agarwal","year":"2017","journal-title":"Clin Ther"},{"issue":"6","key":"pone.0278725.ref040","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.3390\/cancers13061292","article-title":"Targeting BCL-2 in Cancer: Advances, Challenges, and Perspectives","volume":"13","author":"S Hafezi","year":"2021","journal-title":"Cancers"},{"issue":"12","key":"pone.0278725.ref041","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/S1470-2045(10)70261-8","article-title":"Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity","volume":"11","author":"WH Wilson","year":"2010","journal-title":"Lancet Oncol"},{"issue":"6","key":"pone.0278725.ref042","doi-asserted-by":"crossref","first-page":"721","DOI":"10.6004\/jnccn.2019.0028","article-title":"Acute Myeloid Leukemia, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology","volume":"17","author":"MS Tallman","year":"2019","journal-title":"J Natl Compr Canc Netw"},{"issue":"20","key":"pone.0278725.ref043","doi-asserted-by":"crossref","first-page":"2911","DOI":"10.1182\/bloodadvances.2019000243","article-title":"Real-world experience of venetoclax with azacitidine for untreated patients with acute myeloid leukemia","volume":"3","author":"AC Winters","year":"2019","journal-title":"Blood Adv"},{"key":"pone.0278725.ref044","doi-asserted-by":"crossref","first-page":"748766","DOI":"10.3389\/fphar.2021.748766","article-title":"Off-Label Use of Venetoclax in Patients With Acute Myeloid Leukemia: Single Center Experience and Data From Pharmacovigilance Database","volume":"12","author":"L Gozzo","year":"2021","journal-title":"Front Pharmacol"},{"issue":"11","key":"pone.0278725.ref045","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1634\/theoncologist.2017-0055","article-title":"Tumor Lysis Syndrome in Chronic Lymphocytic Leukemia with Novel Targeted Agents","volume":"22","author":"BD Cheson","year":"2017","journal-title":"The Oncologist"},{"key":"pone.0278725.ref046","first-page":"215","volume-title":"Small Molecules in Hematology. Vol 212. Recent Results in Cancer Research","author":"A Scheffold","year":"2018"},{"issue":"14","key":"pone.0278725.ref047","doi-asserted-by":"crossref","first-page":"4264","DOI":"10.1158\/1078-0432.CCR-19-0361","article-title":"Tumor Lysis, Adverse Events, and Dose Adjustments in 297 Venetoclax-Treated CLL Patients in Routine Clinical Practice","volume":"25","author":"LE Roeker","year":"2019","journal-title":"Clin Cancer Res"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0278725","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,7]],"date-time":"2022-12-07T18:42:17Z","timestamp":1670438537000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0278725"}},"subtitle":[],"editor":[{"given":"Jingjing","family":"Qian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2022,12,7]]},"references-count":47,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2022,12,7]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0278725","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,7]]}}}